AR122703A1 - Inhibidores de rip1k - Google Patents
Inhibidores de rip1kInfo
- Publication number
- AR122703A1 AR122703A1 ARP210101712A ARP210101712A AR122703A1 AR 122703 A1 AR122703 A1 AR 122703A1 AR P210101712 A ARP210101712 A AR P210101712A AR P210101712 A ARP210101712 A AR P210101712A AR 122703 A1 AR122703 A1 AR 122703A1
- Authority
- AR
- Argentina
- Prior art keywords
- occurrence
- optionally substituted
- independently
- ora
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
En la presente descripción se describen compuestos inhibidores de quinasa, tales como compuestos inhibidores de proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritas pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) en donde X se selecciona de CH₂, O, S, S(O), S(O)₂ y NRᵃ; Rᵃ para cada aparición se selecciona de hidrógeno, alquilo C₁₋₆ y acilo C₁₋₆; Y¹, Y² y Y³ se seleccionan independientemente del grupo que consiste en N, N(Rᵃ), O, C(Rᵇ)₁₋₂ y C=O; Rᵇ se selecciona de hidrógeno, alquilo C₁₋₆ y halo; Z es C(Rᶜ) o NRᶜ; Rᶜ es una cadena de carbono insaturada C₁₋₄ opcionalmente sustituida con uno o más grupos R¹, opcionalmente interrumpida por 1 ó 2 heteroátomos seleccionados de O, N y S; RZ es N, CH o C(R¹) y junto con ZRᶜ y el carbono al que están unidos, forman un anillo heteroarilo de 5 ó 6 miembros o arilo de 6 miembros sustituido con m grupos R¹; R¹ es un enlazador-grupo R⁶, en donde el enlazador es un enlace, alcanilo (C₁-C₄), alquenilo (C₁-C₄) o alquinilo (C₁-C₄), opcionalmente sustituido por uno o más Rᵇ y R⁶ es Rᵉ, -C(Rᶠ)₃ o -C(Rᶠ)=C(Rᶠ)₂; R² es Rᵃ; el anillo B es heteroarilo de 5 - 10 miembros; R³, para cada aparición, se selecciona independientemente de Rᵇ y ORᵃ; L es O, NRᵃ o alquileno; W es arilo o heteroarilo de 5 - 10 miembros opcionalmente sustituido por p R⁴; R⁴ para cada aparición se selecciona de Rᵇ y ORᵃ; Rᵈ para cada aparición se selecciona independientemente de hidrógeno, alquilo C₁₋₆, aralquilo, arilo o heteroarilo C₅₋₁₀, o dos Rᵈ junto con un nitrógeno al que ambos están conectados forman un grupo heterocíclico C₃₋₁₀ opcionalmente sustituido por uno o más Rᵉ; Rᵉ es independientemente para cada aparición halo, -ORᵈ, -SRᵈ, -S(O)₂Rᵈ, -NRᵈRᵈ, -Si(Rᵃ)₃, -C(O)OH, -C(O)ORᵃ o -C(O)NRᵈRᵈ; Rᶠ es independientemente para cada aparición Rᵃ, Rᵇ o Rᵉ o dos grupos Rᶠ junto con el átomo de carbono unido al mismo proporcionan un grupo cicloalquilo C₃₋₆ o un grupo heterocíclico C₃₋₁₀, cada uno opcionalmente sustituido con uno o más Rᵉ; m es 1, 2, 3 ó 4; n es 0, 1 ó 2; y p es 0, 1, 2, 3, 4 ó 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047194P | 2020-07-01 | 2020-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122703A1 true AR122703A1 (es) | 2022-09-28 |
Family
ID=76972022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101712A AR122703A1 (es) | 2020-07-01 | 2021-06-22 | Inhibidores de rip1k |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11667643B2 (es) |
| EP (1) | EP4175714A1 (es) |
| JP (1) | JP2023532718A (es) |
| KR (1) | KR20230033712A (es) |
| CN (1) | CN116209662A (es) |
| AR (1) | AR122703A1 (es) |
| AU (1) | AU2021300831A1 (es) |
| BR (1) | BR112022026908A2 (es) |
| CA (1) | CA3183296A1 (es) |
| CL (1) | CL2022003812A1 (es) |
| CO (1) | CO2023000051A2 (es) |
| CR (1) | CR20220685A (es) |
| DO (1) | DOP2022000300A (es) |
| EC (1) | ECSP22097749A (es) |
| IL (1) | IL299128A (es) |
| MX (1) | MX2023000138A (es) |
| PE (1) | PE20230730A1 (es) |
| TW (1) | TWI824259B (es) |
| WO (1) | WO2022005898A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| WO2023240379A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
| TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| JP2016514693A (ja) | 2013-03-15 | 2016-05-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハイブリッド型ネクロトーシス阻害剤 |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| JP2018505199A (ja) | 2015-02-13 | 2018-02-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 |
| KR102603915B1 (ko) | 2015-07-02 | 2023-11-21 | 에프. 호프만-라 로슈 아게 | 이환형 락탐 및 이의 사용 방법 |
| DK3362449T3 (da) | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
| JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| KR20180114910A (ko) | 2016-02-05 | 2018-10-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
| CN109843886B (zh) | 2016-10-17 | 2022-04-19 | 豪夫迈·罗氏有限公司 | 二环吡啶酮内酰胺及其使用方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2018154520A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2019134680A1 (zh) | 2018-01-05 | 2019-07-11 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| JP2021523226A (ja) | 2018-05-03 | 2021-09-02 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 |
| ES2947446T3 (es) | 2018-05-03 | 2023-08-09 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de RIP1 y métodos para fabricar y usar los mismos |
| JP2022511213A (ja) | 2018-06-26 | 2022-01-31 | シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ | 細胞壊死阻害剤、その調製方法およびその使用 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| AU2020341681B2 (en) | 2019-09-06 | 2024-02-15 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| CR20220075A (es) | 2019-09-06 | 2022-07-14 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos |
| US11578078B2 (en) | 2019-11-07 | 2023-02-14 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2021
- 2021-06-22 AR ARP210101712A patent/AR122703A1/es unknown
- 2021-06-22 TW TW110122698A patent/TWI824259B/zh active
- 2021-06-25 CR CR20220685A patent/CR20220685A/es unknown
- 2021-06-25 KR KR1020237003542A patent/KR20230033712A/ko active Search and Examination
- 2021-06-25 US US17/358,698 patent/US11667643B2/en active Active
- 2021-06-25 CA CA3183296A patent/CA3183296A1/en active Pending
- 2021-06-25 JP JP2022581403A patent/JP2023532718A/ja active Pending
- 2021-06-25 WO PCT/US2021/039112 patent/WO2022005898A1/en active Application Filing
- 2021-06-25 EP EP21743351.5A patent/EP4175714A1/en active Pending
- 2021-06-25 PE PE2022003090A patent/PE20230730A1/es unknown
- 2021-06-25 BR BR112022026908A patent/BR112022026908A2/pt unknown
- 2021-06-25 AU AU2021300831A patent/AU2021300831A1/en active Pending
- 2021-06-25 CN CN202180053850.6A patent/CN116209662A/zh active Pending
- 2021-06-25 IL IL299128A patent/IL299128A/en unknown
- 2021-06-25 MX MX2023000138A patent/MX2023000138A/es unknown
-
2022
- 2022-12-29 CL CL2022003812A patent/CL2022003812A1/es unknown
- 2022-12-29 DO DO2022000300A patent/DOP2022000300A/es unknown
- 2022-12-30 EC ECSENADI202297749A patent/ECSP22097749A/es unknown
-
2023
- 2023-01-04 CO CONC2023/0000051A patent/CO2023000051A2/es unknown
- 2023-04-26 US US18/307,181 patent/US20230265100A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023532718A (ja) | 2023-07-31 |
| TW202214225A (zh) | 2022-04-16 |
| IL299128A (en) | 2023-02-01 |
| TWI824259B (zh) | 2023-12-01 |
| ECSP22097749A (es) | 2023-03-31 |
| DOP2022000300A (es) | 2023-03-31 |
| US20220009936A1 (en) | 2022-01-13 |
| BR112022026908A2 (pt) | 2023-03-14 |
| EP4175714A1 (en) | 2023-05-10 |
| US11667643B2 (en) | 2023-06-06 |
| WO2022005898A1 (en) | 2022-01-06 |
| CA3183296A1 (en) | 2022-01-06 |
| MX2023000138A (es) | 2023-04-11 |
| AU2021300831A1 (en) | 2023-01-19 |
| PE20230730A1 (es) | 2023-05-03 |
| US20230265100A1 (en) | 2023-08-24 |
| CO2023000051A2 (es) | 2023-04-17 |
| CL2022003812A1 (es) | 2023-08-18 |
| CR20220685A (es) | 2023-03-28 |
| KR20230033712A (ko) | 2023-03-08 |
| CN116209662A (zh) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR110990A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR106963A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR122703A1 (es) | Inhibidores de rip1k | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR098316A1 (es) | Derivados pirazolicos condensados, composiciones y métodos para modular los receptores x farnesoides | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR121717A1 (es) | Inhibidores de rip1k | |
| AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR111874A1 (es) | Derivados de pirimidina | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR111282A1 (es) | Inhibidores de cdpk1 ii, composiciones y métodos relacionados con los mismos |